Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.46 |
| ▸ | MOGAT2 | Q3SYC2 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTR5A | P47898 | 1/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.34 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7297828 | 0.86 | GAA (0.55) | GAACREBBPMOGAT2KMT2AMEN1 | |
| SCHEMBL9511664 | 0.82 | GAA (0.57) | GAACREBBPMOGAT2KMT2AMEN1 | |
| SCHEMBL9511671 | 0.82 | GAA (0.57) | GAACREBBPMOGAT2KMT2AMEN1 | |
| SCHEMBL11327486 | 0.82 | GAA (0.57) | GAACREBBPMOGAT2KMT2AMEN1 | |
| SCHEMBL9701618 | 0.82 | GAA (0.45) | GAACREBBPMOGAT2LMNAMAPT | |
| SCHEMBL7298355 | 0.80 | GAA (0.52) | GAAMOGAT2KMT2AMEN1LMNA | |
| SCHEMBL11337711 | 0.79 | GAA (0.55) | GAACREBBPMOGAT2KMT2AMEN1 | |
| SCHEMBL24179180 | 0.78 | GAA (0.54) | GAACREBBPMOGAT2KMT2AMEN1 | |
| SCHEMBL20867680 | 0.78 | GAA (0.54) | GAACREBBPMOGAT2KMT2AMEN1 | |
| SCHEMBL10476939 | 0.78 | GAA (0.54) | GAACREBBPMOGAT2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1847232-A | 2,3-dihydro-3-hydroxymethyl-[1,4]-benzoxazine derivative and its prepn process | UNIV SHANDONG (CN) | 2006-10-18 | — | — | CN | claimed |
| EP-3686196-A1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | Hangzhou Innogate Pharma Co., Ltd. (CN) | 2020-07-29 | — | — | EP | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| CN-1847232-A | 2,3-dihydro-3-hydroxymethyl-[1,4]-benzoxazine derivative and its prepn process | UNIV SHANDONG (CN) | 2006-10-18 | — | — | CN | disclosed |
| CN-1847232-A | 2,3-dihydro-3-hydroxymethyl-[1,4]-benzoxazine derivative and its prepn process | UNIV SHANDONG (CN) | 2006-10-18 | — | — | CN | disclosed |
| CN-1847232-A | 2,3-dihydro-3-hydroxymethyl-[1,4]-benzoxazine derivative and its prepn process | UNIV SHANDONG (CN) | 2006-10-18 | — | — | CN | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
| US-5112820-A | Vision defects | STERLING DRUG INC. (US) | 1992-05-12 | — | — | US | disclosed |
| US-5109135-A | 2- or 3-aminomethyl-4-amino-3,4-dihydro-2H-1,4-benzoxazine intermediates | STERLING DRUG INC. (US) | 1992-04-28 | — | — | US | disclosed |
| US-5066803-A | Chemical intermediates for analgesics | STERLING DRUG INC. (US) | 1991-11-19 | — | — | US | disclosed |
| WO-1990007505-A1 | 2- AND 3-AMINOMETHYL-6-ARYLCARBONYL-2,3-DIHYDROPYRROLO[1,2,3-de]-1,4-BENZOXAZINES | STERLING DRUG INC. (US) | 1990-07-12 | — | — | WO | disclosed |
| US-4939138-A | 2- and 3-aminomethyl-6-arylcarbonyl-2,3-dihydropyrrolo(1,2,3-DE)-1,4-benzoxazines | STERLING DRUG INC. (US) | 1990-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | GAA 3884/4885CREBBP 1880/4885MOGAT2 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.